Compare Crispr Therapeutics AG (CRSP) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Logitech International SA — how do they compare? Crispr Therapeutics AG trades at $53.88 (market cap $5.17B), while Logitech International SA trades at $103.82 (market cap $15.18B). The key difference: Logitech International SA is far larger — about 2.9× Crispr Therapeutics AG's market cap, and Logitech International SA pays a 1.62% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | LOGI | |
|---|---|---|
Market Cap | $5.17B | $15.18B |
Sector | Health | Technology |
52-Week High | $76.78 | $126.69 |
52-Week Low | $44.34 | $85.84 |
Enterprise Value | $3.59B | $13.52B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.
The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.
Logitech (LOGI) trades at $106.33, up 3.26% today, with a bullish technical signal from moving averages and recent earnings beats. Revenue is projected to grow to $4.9B in 2026, with net income margin improving to 16.27%. The company faces near-term supply chain risks from a key semiconductor supplier shutdown, but strong demand in gaming and premium devices supports growth.
The outlook is mixed: solid fundamentals and analyst consensus target of $109.75 suggest upside, but supply constraints and mixed analyst ratings (26% Buy, 47% Hold, 26% Sell) indicate caution. Investors should weigh robust profitability against operational risks in the coming quarters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
